An interventional study of Neurostimulation System (NSS): Active Setting and Neurostimulation System (NSS): Sham Setting in Major Depressive Disorder and Treatment Resistant Depression, sponsored by Klaus Martiny. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by Klaus Martiny · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Depressive Disorder, Major with a site in Denmark — 10 open to participants now, 11 under way, none of them phase 3. Depressive Disorder, Major · Denmark.
Among the 44 studies in Depressive Disorder, Major with a site in Denmark, this one is the 27th largest by planned enrollment of the 36 interventional ones that give a count, is the only one that started in 2023, is one of 24 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 34th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →10 of the 44 studies in Depressive Disorder, Major with a site in Denmark are open now. Recruiting first, the newest first:
Anders Jørgensen · Sites in Denmark
Ages 18+
Aalborg University Hospital · Sites in Denmark
Ages 18–65
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital · Sites in Denmark
Ages 18–60
Nordsjaellands Hospital · Sites in Denmark
Ages 18–65
University Medical Center Groningen · Sites in Denmark, Czechia, Netherlands and 1 more country
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 5 · Phase 4 4
First in 2002; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 80 across the 36 interventional studies, 78 across the 8 observational. Of the 31 that completed or were terminated, 4 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 44 have an industry lead sponsor. The 10 most frequent:
Klaus Martiny is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Klaus Martiny has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
7 of the studies in Depressive Disorder, Major with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05616559Rigshospitalet, DenmarkPrecision Medicine in the Depression Treatment | 2026-12 |
| NCT04685148Vibe G Frøkjær, MD, PhDMaternal Mental Health Trial | 2026-12-31 |
| NCT06782724University Medical Center GroningenPsilocybin Therapy for Psychological Distress in Palliative Patients | 2027-01-01 |
| NCT07263321Aalborg University HospitalImproving Treatment for Depression in General Practice Using a Step-by-Step Care Plan. | 2027-06 |
| NCT05680220Klaus Martiny40 Hz Light Neurostimulation for Patients With Depression (FELIX) | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 44 studies in Depressive Disorder, Major with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Recent research in mice models of Alzheimer's disease (AD) has demonstrated that one hour per day of exposure to 40 Hz flickering light therapy can halt the disease's progression, and improve cognition and memory. Moreover, recent data suggest that 40 Hz light stimulation may induce neuroplasticity and reduce neuroinflammation.
In this study, the investigators aim to evaluate the antidepressant effects of 40 Hz light stimulation in Major Depressive Disorder (MDD). Patients will be exposed to 40 Hz invisible spectral flickering light (active setting) or continuous non-flickering white light (sham setting) in a home setting for 1 hour each day.
Major depression is a major societal challenge worldwide and a substantial proportion of patients do not attain remission. Major depressive disorder (MDD) bears several key neurobiological similarities with Alzheimer's Disease, namely cognitive deficits, impaired neuroplasticity, neurodegeneration, and neuroinflammation. Inducing neuroplasticity and reducing neuroinflammation are thought to be key cellular targets in the treatment of MDD. However, 40 Hz light stimulation research in the context of MDD is limited.
In this double-blinded, randomized placebo-controlled trial the primary objective is to investigate the antidepressant effect of a non-invasive neurostimulation therapy using a 40 Hz masked flickering light. This study utilizes a novel way of masking light by alternating the spectral composition of white light, resulting in the flicker unnoticeable to human perception.
The primary outcome measure of this study is the estimated difference in the Hamilton Depression Rating sub-scale (HAM-D6) scores between groups at week 6. Furthermore, investigators want to assess whether 40 Hz masked flickering light therapy produces a similar early shift in neural and cognitive response to emotional information seen with antidepressant therapy and whether this predicts treatment efficacy. Suicidal ideation, sleep patterns, and quality of life will be also investigated in order to evaluate the 40 Hz masked flickering light stimulation effects on other symptoms of depression. Explorative analysis of the EEG data will be performed from baseline to week 6 for the further development and validation of EEG-based biomarkers.
A total of 60 participants will be enrolled for a six weeks treatment period followed by a two weeks follow-up period. Participants will be recruited from a psychotherapeutic outpatient unit. Medication should be unchanged for the last 4 weeks and during the study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Exposure to the NSS device set to 40 Hz invisible spectral flicker 1 hour a day
Exposure to the NSS device set to continuous color-matched white light for 1 hour a day
Exposure to the active device for 1 hour a day for 6 weeks
Exposure to the sham device for 1 hour a day for 6 weeks
Depression severity measured by Hamilton Depression Rating sub-scale (HAM-D6)
The HAM-D6 scale is designed to rate the severity of depression by a healthcare professional. The assessment scale contains 6 items pertaining to the symptoms of depression experienced over the week. The primary endpoint is the mean difference in scores between treatments at baseline and week 6. The score range is from, 0-24 (24=highest depression level).
Time frame: Baseline and week 6
Self-reported depression symptoms measured by Major Depression Inventory (MDI)
The MDI is a depression self-assessment questionnaire. It consists of the 10 ICD-10 symptoms for depression. The sum of 10 questions indicates the degree of depression. The score range is from 0-50 (50=highest depression level).
Time frame: Baseline, week 1, 3, 6 and 8.
Cognition measured by Facial Expression Recognition Test (FERT)
Assessing attention and recognition of emotional facial expressions using the FERT. The outcome is accuracy (% correct expressions identified, range: 0-100, higher is better) and response times for accurate identifications (milliseconds, range can vary quite a bit, smaller number is better because it reflect higher speed).
Time frame: Baseline, week 1 and 6
Cognition measured by Emotional Categorization and Memory test (ECMT)
Assessing self-referent memory for emotional words using the ECMT. Outcome is response times for correct identifications during encoding phase (milliseconds, smaller better) and for recall phase: number of positive and negative words recalled (higher is better)
Time frame: Baseline, week 1 and 6
Cognition measured by Screen for Cognitive Impairment in Psychiatry (SCIP)
Non-emotional cognition is investigated with the SCIP. Outcomes is total score as well as scores for the five subtests, in all cases higher is better (numbers correct)
Time frame: Baseline, week 1 and 6
Cognition measured by Trail Making Test B (TMT- B)
Non-emotional cognition investigated with the Trail Making Test B (TMT- B). Outcome is time in seconds to complete the task, lower is better (higher speed)
Time frame: Baseline, week 1 and 6
Sleep quality measured by Pittsburgh Sleep Quality Index (PSQI)
PSQI consist of seven component scores that are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality. A cut-off of 5 is recognized a indicative of sleep problems.
Time frame: Baseline, week 3, 6 and 8
Sleep duration
Average sleep duration assessed over last 7 days will be logged by the participants using a sleep diary.
Time frame: Baseline, week 3, 6 and 8
Sleep timing
Average sleep timing will be assessed over last 7 days logged by the participants using a sleep diary.
Time frame: Baseline, week 3, 6 and 8
Quality of Life measured by WHO quality of life index (WHO-5)
The WHO-5 score ranges from 0 to 25, with 0 representing worst possible and 25 representing best possible quality of life. To obtain a percentage score ranging from 0 to 100, the raw score is multiplied by 4. A percentage score of 0 represents worst possible, whereas a score of 100 represents best possible quality of life. A 10% difference indicates a significant change.
Time frame: Baseline, week 3,6 and 8
Plan to share: No
Started Oct 2023 (actual). Primary completion is estimated for Jun 2027, 44 months after the start.
Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 44 months is above that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Klaus Martiny